- $272.99m
- $254.79m
- 39
- 14
- 76
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 14.94 | ||
| Price to Tang. Book | 14.94 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -82.65% | ||
| Return on Equity | -57.64% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Enlivex Ltd, formerly known as Enlivex Therapeutics Ltd, is an Israel-based clinical-stage macrophage reprogramming immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to restore macrophages to their homeostatic state. The Company focuses on diseases in which macrophages are pathologically reprogrammed, such as solid cancers, sepsis and COVID‑19, where non-homeostatic macrophages contribute significantly to disease severity. By re-establishing macrophage homeostasis, Allocetra has the potential to provide an immunotherapeutic mechanism of action for life-threatening indications defined as unmet medical needs, either as a stand‑alone therapy or in combination with other treatments.
Directors
- Oren Hershkovitz CEO (44)
- Shai Novik VCH (55)
- Dror Mevorach FDR (65)
- Shachar Shlosberger CFO (44)
- Baruch Halpert DRC (54)
- Bernhard Kirschbaum DRC (62)
- Sangwoo Lee DRC (49)
- Brian Schwartz DRC (49)
- Michel Habib IND (54)
- Gili Hart IND (46)
- Abraham Havron IND (73)
- Last Annual
- December 31st, 2024
- Last Interim
- September 30th, 2025
- Incorporated
- January 22nd, 2012
- Public Since
- July 30th, 2014
- No. of Shareholders
- 86
- No. of Employees
- 36
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 237,381,498
- Address
- 14 Einstein St., NESS-ZIONA, 7403618
- Web
- https://www.enlivex.com/
- Phone
- +972 86623301
- Auditors
- Yarel Partners
Upcoming Events for ENLV
Q1 2026 Enlivex Therapeutics Ltd Earnings Release
Similar to ENLV
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Enlivex share price?
As of Today at 19:28 UTC, shares in Enlivex are trading at $1.10. This share price information is delayed by 15 minutes.
How has the Enlivex share price performed this year?
Shares in Enlivex last closed at $1.10 and the price had moved by +12.24% over the past 365 days. In terms of relative price strength the Enlivex share price has underperformed the S&P500 Index by -3.75% over the past year.
What are the analyst and broker recommendations for Enlivex?
The overall consensus recommendation for Enlivex is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Enlivex dividend yield?
Enlivex does not currently pay a dividend.
Does Enlivex pay a dividend?
Enlivex does not currently pay a dividend.
When does Enlivex next pay dividends?
Enlivex does not currently pay a dividend.
How do I buy Enlivex shares?
To buy shares in Enlivex you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Enlivex?
As of the previous close price of $1.10, shares in Enlivex had a market capitalisation of $272.99m.
Where are Enlivex shares listed?
Here are the trading details for Enlivex:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ENLV
What kind of share is Enlivex?
Based on an overall assessment of its quality, value and momentum Enlivex is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Enlivex share price forecast for 2026?
The analyst consensus target price for shares in Enlivex is $12.43. That is 1030.43% above the last closing price of $1.10.
Analysts covering Enlivex currently have a consensus Earnings Per Share (EPS) forecast of -$0.40 for the next financial year.
Find out moreWhat is the trend in the Enlivex share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Enlivex. Over the past six months, its share price has underperformed the S&P500 Index by -3.24%.
As of the last closing price of $1.10, shares in Enlivex were trading +2.8% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Enlivex PE Ratio?
The Enlivex PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Enlivex?
Enlivex's management team is headed by:
- Oren Hershkovitz - CEO
- Shai Novik - VCH
- Dror Mevorach - FDR
- Shachar Shlosberger - CFO
- Baruch Halpert - DRC
- Bernhard Kirschbaum - DRC
- Sangwoo Lee - DRC
- Brian Schwartz - DRC
- Michel Habib - IND
- Gili Hart - IND
- Abraham Havron - IND